vs
爱齐科技（ALGN）与TENET HEALTHCARE CORP（THC）财务数据对比。点击上方公司名可切换其他公司
TENET HEALTHCARE CORP的季度营收约是爱齐科技的5.3倍（$5.5B vs $1.0B）。爱齐科技净利率更高（13.0% vs 11.7%，领先1.3%）。TENET HEALTHCARE CORP同比增速更快（9.0% vs 5.3%）。TENET HEALTHCARE CORP自由现金流更多（$367.0M vs $187.3M）。过去两年爱齐科技的营收复合增速更高（2.5% vs 1.5%）
爱齐科技是一家全球知名医疗设备企业，主营设计、生产及销售隐适美透明矫治器、iTero口内扫描仪及配套服务，客户覆盖正畸医师、全科牙医，面向修复、美容牙科领域，业务分为透明矫治器、扫描仪及服务两大板块，可满足青少年等不同群体的正畸需求
Tenet Healthcare Corporation是总部位于美国达拉斯的营利性跨国医疗服务企业，旗下拥有USPI等多个品牌、子公司、合资企业及合作主体，运营65家医院及超过450个医疗设施，还通过旗下Conifer Health Solutions为各类医疗系统及其他客户提供专业医疗支持服务
ALGN vs THC — 直观对比
营收规模更大
THC
是对方的5.3倍
$1.0B
营收增速更快
THC
高出3.7%
5.3%
净利率更高
ALGN
高出1.3%
11.7%
自由现金流更多
THC
多$179.7M
$187.3M
两年增速更快
ALGN
近两年复合增速
1.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $5.5B |
| 净利润 | $135.8M | $644.0M |
| 毛利率 | 65.3% | — |
| 营业利润率 | 14.8% | 15.4% |
| 净利率 | 13.0% | 11.7% |
| 营收同比 | 5.3% | 9.0% |
| 净利润同比 | 30.8% | 12.6% |
| 每股收益（稀释后） | $1.88 | $4.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALGNTHC
| Q4 25 | $1.0B | $5.5B | ||
| Q3 25 | $995.7M | $5.3B | ||
| Q2 25 | $1.0B | $5.3B | ||
| Q1 25 | $979.3M | $5.2B | ||
| Q4 24 | $995.2M | $5.1B | ||
| Q3 24 | $977.9M | $5.1B | ||
| Q2 24 | $1.0B | $5.1B | ||
| Q1 24 | $997.4M | $5.4B |
净利润ALGNTHC
| Q4 25 | $135.8M | $644.0M | ||
| Q3 25 | $56.8M | $579.0M | ||
| Q2 25 | $124.6M | $522.0M | ||
| Q1 25 | $93.2M | $622.0M | ||
| Q4 24 | $103.8M | $572.0M | ||
| Q3 24 | $116.0M | $681.0M | ||
| Q2 24 | $96.6M | $477.0M | ||
| Q1 24 | $105.0M | $2.3B |
毛利率ALGNTHC
| Q4 25 | 65.3% | — | ||
| Q3 25 | 64.2% | — | ||
| Q2 25 | 69.9% | — | ||
| Q1 25 | 69.5% | — | ||
| Q4 24 | 70.0% | — | ||
| Q3 24 | 69.7% | — | ||
| Q2 24 | 70.3% | — | ||
| Q1 24 | 70.0% | — |
营业利润率ALGNTHC
| Q4 25 | 14.8% | 15.4% | ||
| Q3 25 | 9.7% | 16.8% | ||
| Q2 25 | 16.1% | 15.6% | ||
| Q1 25 | 13.4% | 18.1% | ||
| Q4 24 | 14.5% | 16.2% | ||
| Q3 24 | 16.6% | 21.3% | ||
| Q2 24 | 14.3% | 14.9% | ||
| Q1 24 | 15.5% | 61.2% |
净利率ALGNTHC
| Q4 25 | 13.0% | 11.7% | ||
| Q3 25 | 5.7% | 10.9% | ||
| Q2 25 | 12.3% | 9.9% | ||
| Q1 25 | 9.5% | 11.9% | ||
| Q4 24 | 10.4% | 11.3% | ||
| Q3 24 | 11.9% | 13.3% | ||
| Q2 24 | 9.4% | 9.3% | ||
| Q1 24 | 10.5% | 43.5% |
每股收益（稀释后）ALGNTHC
| Q4 25 | $1.88 | $4.22 | ||
| Q3 25 | $0.78 | $3.86 | ||
| Q2 25 | $1.72 | $3.14 | ||
| Q1 25 | $1.27 | $4.27 | ||
| Q4 24 | $1.40 | $3.79 | ||
| Q3 24 | $1.55 | $4.89 | ||
| Q2 24 | $1.28 | $2.64 | ||
| Q1 24 | $1.39 | $21.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $2.9B |
| 总债务越低越好 | — | $13.1B |
| 股东权益账面价值 | $4.0B | $4.2B |
| 总资产 | $6.2B | $29.7B |
| 负债/权益比越低杠杆越低 | — | 3.10× |
8季度趋势，按日历期对齐
现金及短期投资ALGNTHC
| Q4 25 | $1.1B | $2.9B | ||
| Q3 25 | $1.0B | $3.0B | ||
| Q2 25 | $901.2M | $2.6B | ||
| Q1 25 | $873.0M | $3.0B | ||
| Q4 24 | $1.0B | $3.0B | ||
| Q3 24 | $1.0B | $4.1B | ||
| Q2 24 | $761.4M | $2.9B | ||
| Q1 24 | $865.8M | $2.5B |
总债务ALGNTHC
| Q4 25 | — | $13.1B | ||
| Q3 25 | — | $13.1B | ||
| Q2 25 | — | $13.1B | ||
| Q1 25 | — | $13.1B | ||
| Q4 24 | — | $13.1B | ||
| Q3 24 | — | $12.8B | ||
| Q2 24 | — | $12.8B | ||
| Q1 24 | — | $12.8B |
股东权益ALGNTHC
| Q4 25 | $4.0B | $4.2B | ||
| Q3 25 | $4.0B | $4.0B | ||
| Q2 25 | $3.9B | $3.7B | ||
| Q1 25 | $3.8B | $4.2B | ||
| Q4 24 | $3.9B | $4.2B | ||
| Q3 24 | $3.9B | $3.8B | ||
| Q2 24 | $3.8B | $3.5B | ||
| Q1 24 | $3.8B | $3.5B |
总资产ALGNTHC
| Q4 25 | $6.2B | $29.7B | ||
| Q3 25 | $6.2B | $29.4B | ||
| Q2 25 | $6.2B | $28.7B | ||
| Q1 25 | $6.1B | $29.2B | ||
| Q4 24 | $6.2B | $28.9B | ||
| Q3 24 | $6.4B | $29.4B | ||
| Q2 24 | $6.2B | $29.3B | ||
| Q1 24 | $6.2B | $28.9B |
负债/权益比ALGNTHC
| Q4 25 | — | 3.10× | ||
| Q3 25 | — | 3.26× | ||
| Q2 25 | — | 3.49× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | — | 3.14× | ||
| Q3 24 | — | 3.33× | ||
| Q2 24 | — | 3.67× | ||
| Q1 24 | — | 3.70× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $223.2M | $731.0M |
| 自由现金流经营现金流 - 资本支出 | $187.3M | $367.0M |
| 自由现金流率自由现金流/营收 | 17.9% | 6.6% |
| 资本支出强度资本支出/营收 | 3.4% | 6.6% |
| 现金转化率经营现金流/净利润 | 1.64× | 1.14× |
| 过去12个月自由现金流最近4个季度 | $490.8M | $2.5B |
8季度趋势，按日历期对齐
经营现金流ALGNTHC
| Q4 25 | $223.2M | $731.0M | ||
| Q3 25 | $188.7M | $1.1B | ||
| Q2 25 | $128.7M | $936.0M | ||
| Q1 25 | $52.7M | $815.0M | ||
| Q4 24 | $286.1M | $-331.0M | ||
| Q3 24 | $263.7M | $1.0B | ||
| Q2 24 | $159.8M | $747.0M | ||
| Q1 24 | $28.7M | $586.0M |
自由现金流ALGNTHC
| Q4 25 | $187.3M | $367.0M | ||
| Q3 25 | $169.0M | $778.0M | ||
| Q2 25 | $107.2M | $743.0M | ||
| Q1 25 | $27.4M | $642.0M | ||
| Q4 24 | $263.1M | $-661.0M | ||
| Q3 24 | $233.9M | $829.0M | ||
| Q2 24 | $106.4M | $602.0M | ||
| Q1 24 | $19.3M | $346.0M |
自由现金流率ALGNTHC
| Q4 25 | 17.9% | 6.6% | ||
| Q3 25 | 17.0% | 14.7% | ||
| Q2 25 | 10.6% | 14.1% | ||
| Q1 25 | 2.8% | 12.3% | ||
| Q4 24 | 26.4% | -13.0% | ||
| Q3 24 | 23.9% | 16.2% | ||
| Q2 24 | 10.3% | 11.8% | ||
| Q1 24 | 1.9% | 6.4% |
资本支出强度ALGNTHC
| Q4 25 | 3.4% | 6.6% | ||
| Q3 25 | 2.0% | 5.3% | ||
| Q2 25 | 2.1% | 3.7% | ||
| Q1 25 | 2.6% | 3.3% | ||
| Q4 24 | 2.3% | 6.5% | ||
| Q3 24 | 3.0% | 4.2% | ||
| Q2 24 | 5.2% | 2.8% | ||
| Q1 24 | 0.9% | 4.5% |
现金转化率ALGNTHC
| Q4 25 | 1.64× | 1.14× | ||
| Q3 25 | 3.33× | 1.83× | ||
| Q2 25 | 1.03× | 1.79× | ||
| Q1 25 | 0.57× | 1.31× | ||
| Q4 24 | 2.76× | -0.58× | ||
| Q3 24 | 2.27× | 1.53× | ||
| Q2 24 | 1.66× | 1.57× | ||
| Q1 24 | 0.27× | 0.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALGN
暂无分部数据
THC
| Other | $2.9B | 52% |
| Health Care Patient Service | $1.4B | 25% |
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $1.2B | 22% |
| Health Care Other Sources | $56.0M | 1% |
